Results 91 to 100 of about 3,701,935 (349)

Periodontal manifestations as related to the cytokines in the gingival crevicular fluid

open access: yesIndian Journal of Dental Sciences, 2021
Backround: Periodontal diseases are classified into different categories based on the clinical symptoms and related to these there can be changes in the cytokine levels in the connective tissue and elaboration of these in the gingival crevicular fluid ...
Nymphea Pandit, Neeta Bhavsar
doaj   +1 more source

Evaluating the involvement of autolysosomes in the nuclear translocation of fluorescent proteins

open access: yesFEBS Open Bio, EarlyView.
Endogenously expressed fluorescent proteins can be degraded by autophagy and transported to cell nuclei via the nuclear pore complex. But in some cell lines, for example, HeLa cells which are positive for immunoreactivity of a receptor ligand, such as UCN I, in cell nuclei, fusion of autolysosome with the nuclear envelope is involved in the nuclear ...
Keiichi Ikeda
wiley   +1 more source

Validation of an automated enzyme immunoassay for interleukin-6 for routine clinical use [PDF]

open access: yes, 1998
Serum levels of Interleukin-6 (IL-6), a proinflammatory cytokine, are increased in early stages of inflammatory diseases such as infection and sepsis. Assay systems which permit its measurement within a few hours and as a single measurement have not been
Peter Fraunberger   +17 more
core   +1 more source

Identification of fused pyrimidines as interleukin 17 secretion inhibitors [PDF]

open access: yes, 2018
Inhibiting the interleukin 17 pathway is of interest in a number of autoimmune diseases. Herein, 42 fused pyrimidines have been evaluated as interleukin 17 secretion inhibitors using a phenotypic assay with peripheral blood mononuclear cells.
Sundby, Eirik   +7 more
core   +3 more sources

Interleukin 17 enhances bone morphogenetic protein-2-induced ectopic bone formation

open access: yesScientific Reports, 2018
Interleukin 17 (IL-17) stimulates the osteogenic differentiation of progenitor cells in vitro through a synergy with bone morphogenetic protein (BMP)-2. This study investigates whether the diverse responses mediated by IL-17 in vivo also lead to enhanced
M. Croes   +6 more
doaj   +1 more source

Evaluation of interleukin 17: A polymorphism in patients with visceralleishmaniasis [PDF]

open access: yesJournal of Analytical Research in Clinical Medicine, 2014
Introduction: Visceral leishmaniasis (VL) is an infectious disease that it has spread in more than 60 countries, in Iran it is caused by Leishmania infantum.
Safar Sadighi   +3 more
doaj   +1 more source

Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis

open access: yesActa Dermato-Venereologica, 2020
Anti-interleukin-17 agents have recently been developed for the treatment of psoriasis. This study evaluated the tolerance and effectiveness of anti-interleukin-17 agents for psoriasis in elderly patients in daily practice.
C. Phan   +31 more
semanticscholar   +1 more source

Loss of AMBRA1 activates MAPK and angiogenesis signaling pathways in melanoma cells

open access: yesFEBS Open Bio, EarlyView.
Loss of AMBRA1 in melanoma cells activates multiple oncogenic pathways associated with tumor progression. Transcriptomic and protein network analyses revealed that AMBRA1 depletion enhances MAPK/ERK signaling, angiogenesis, TGF‐β/EMT signaling, and Wnt/axon guidance pathways.
Milad Ibrahim   +4 more
wiley   +1 more source

Milk fat globule E-8 and interleukin 17 in systemic lupus erythematosus: partners in crime? [PDF]

open access: yes, 2016
Objectives: Systemic lupus erythematosus (SLE) is a multi-factorial, autoimmune disease with a wide array of manifestations. The pro-inflammatory cytokine interleukin (IL)-17 has been implicated in the inflammatory response and tissue damage in SLE ...
Fatema Elgengehy   +3 more
core   +1 more source

Evaluation of the efficacy and safety of an interleukin-17 inhibitor in hospitalized COVID-19 patients

open access: yesConsilium Medicum
Aim. To evaluate the clinical efficacy and safety of netakimab (an interleukin-17 inhibitor) in hospitalized patients with severe COVID-19. Materials and methods. A retrospective case-control study was conducted involving 171 patients. The main group (
Zamira M. Merzhoeva   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy